Annals of Oncology

This is the paper Europe PMC returns for registry id NCT04493853 with the most citations, so it is the natural first reading for anyone following the CAPItello-281 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

The latest in a line of negative targeted-therapy trials in triple-negative disease (EGFR, VEGF, iniparib, now AKT): a modest delay in progression that did not translate into survival, in the same year that an antibody-drug conjugate did. It is why the roadmap treats pathway-targeted small molecules as the road not taken.

This is the paper Europe PMC returns for registry id NCT03742102 with the most citations, so it is the natural first reading for anyone following the BEGONIA trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

The first-line overall survival result that made an antibody-drug conjugate the standard for PD-L1-negative or immunotherapy-ineligible metastatic triple-negative disease, and the reason the sequencing question (which TROP2 drug first, what after it) is now urgent.

A second publication from the KEYNOTE-671 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

One of the most cited trial reports Europe PMC returns for Trastuzumab deruxtecan in HR-positive / HER2-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.

A second publication from the monarchE trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

A second publication from the trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

Answers the two questions that hung over adjuvant olaparib, durability and late leukaemia, in its favour; the remaining question is whether carriers who also received pembrolizumab or capecitabine, whom the trial did not study, get the same benefit.

This is the paper Europe PMC returns for registry id NCT03975647 with the most citations, so it is the natural first reading for anyone following the HER2CLIMB-02 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT02938299 with the most citations, so it is the natural first reading for anyone following the Neoadjuvant L19IL2 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT03778229 with the most citations, so it is the natural first reading for anyone following the SAVANNAH trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT05722015 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

Platinum and immunotherapy are now consensus for early triple-negative disease; the open votes have moved to who can safely receive less.

For a fast-moving disease the living guideline, not the 2021 paper, is where European recommendations for triple-negative breast cancer now change; readers should check the website rather than the journal.

This is the European standard the UK page for triple-negative breast cancer is compared against; NICE guidance covers the same ground with a narrower set of funded drugs.

An off-the-shelf alternative to CAR-T for repeatedly relapsed follicular lymphoma: no apheresis, no manufacturing wait, and a complete response rate in the same range, at the cost of continued treatment rather than a single infusion.

It is the positive half of the tumour mutational burden story and it applies only to single-agent immunotherapy, which is the setting fewest patients are treated in.

This is the reference European standard against which UK and NHS practice for gallbladder cancer is compared; it treats gallbladder cancer within biliary tract cancer rather than as its own disease.

The split between favourable and unfavourable cancer of unknown primary on OnCo, and the treatment on each page, follow this guideline.

This is the European standard the UK and NHS page for colorectal cancer is compared against; NICE NG151 covers the same ground for England with a narrower set of funded drugs.

A second publication from the trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

This is the European standard the UK and NHS page for pancreatic cancer is compared against; NICE guideline NG85 (2018) covers the same ground with an older evidence base and a narrower set of funded drugs.

The first prospective test of acting on ctDNA in triple-negative disease, and a negative one: with a quarterly, single-mutation assay the window between detectable DNA and visible metastasis was too short to intervene. Later designs use tumour-informed assays, earlier sampling and drugs with more single-agent activity.

St Gallen is where de-escalation questions in triple-negative disease (who needs the full KEYNOTE-522 regimen, who can skip adjuvant pembrolizumab) are first put to a vote; the 2023 panel framed intensity and duration as the central problem.

A second publication from the ROAR trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

The third trial to show carboplatin's benefit persists beyond pathological complete response and the trial that closed the neoadjuvant PARP inhibitor route in unselected triple-negative disease; PARP inhibition survives only in germline BRCA carriers.

Two term pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

The survival result that moved adjuvant olaparib from a disease-free survival approval to an undisputed standard, and the reason germline testing at diagnosis of triple-negative breast cancer is now a treatment decision rather than a family history exercise.

A second publication from the KEYNOTE-158 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

A second publication from the SOLAR-1 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

TROP2 IHC does not gate sacituzumab govitecan: the label requires no test, and the corpus records TROP2 as an expression readout without a threshold.

The chondrosarcoma page's recommendations for curettage of low-grade limb lesions, wide resection for higher grades and particle therapy for skull base tumours follow this guideline.

ctDNA clearance may refine pCR as a surrogate: a patient with residual disease but no ctDNA may not need escalation, the hypothesis behind ctDNA-guided post-neoadjuvant trials.

Methylation-based screening is real but weakest exactly where pancreatic cancer needs it, at stage I, which is why high-risk surveillance rather than population screening carries the field here.

The document that made immunotherapy, PARP inhibition and the first antibody-drug conjugate the European standard for metastatic triple-negative disease; every later first-line change is an amendment to it.

Most decisions on the localised and metastatic anal cancer pages, from the chemoradiotherapy schedule to when to operate and what to give for metastatic disease, follow this guideline or its American counterpart.

One of the most cited papers Europe PMC returns for Jean-Pascal Machiels at King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.

One of the most cited trial reports Europe PMC returns for Mirvetuximab soravtansine in Ovarian cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.

This is the paper Europe PMC returns for registry id NCT03125902 with the most citations, so it is the natural first reading for anyone following the IMpassion131 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

The general principles on the sarcoma subtype pages (reference centre surgery, radiotherapy for high-grade deep tumours, doxorubicin first line, histology-directed later lines) follow this guideline.

Acral melanoma needs its own treatment evidence: anti-PD-1 monotherapy has limited activity, so combination immunotherapy, KIT-directed therapy and trials of CDK4/6 inhibitors are important options.

The European rulebook for what happens after a colon cancer operation, and the reason a patient with a T3 N1 tumour is now offered three months of chemotherapy rather than six.

The site-specific and stage-specific approach on the marginal zone lymphoma page follows this guideline.

TMB-high is uncommon but not negligible in TNBC, rises at relapse, and the tumour-agnostic pembrolizumab indication makes it worth measuring on a metastatic biopsy.

One of the most cited papers Europe PMC returns for Jean-Pascal Machiels at King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.

A second publication from the ALEX trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

One of the most cited papers Europe PMC returns for Peter Thuss-Patience at Charité Universitätsmedizin Berlin, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.

Postoperative ctDNA marks a group that current adjuvant chemotherapy does not cure, the rationale for ctDNA-guided intensification trials.

A second publication from the OlympiAD trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

TILs are prognostic without chemotherapy, which is what a de-escalation biomarker has to show before trials omit treatment on its basis.

NTRK fusions are under 0.5% of pancreatic cancers but carry a tumour-agnostic approval; this case is the published proof that the label applies here.

One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

Androgen receptor testing and androgen deprivation therapy are now standard options for salivary duct carcinoma, often before chemotherapy in slowly progressing disease.

The observation after complete surgery for stage I granulosa cell tumour, lifelong inhibin monitoring and endocrine or bevacizumab-based options at relapse follow this guideline.

One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

One of the most cited papers Europe PMC returns for Robin L. Jones at The Royal Marsden, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.

The survival evidence behind platinum in early triple-negative disease, and the first large demonstration that most triple-negative tumours are DNA-repair deficient whether or not BRCA is mutated, which is why HRD scores have not become a platinum selection test.

This is the sourced bridge between expression subtype and mutation: it tells a clinician that a LAR tumour is the one to sequence for PIK3CA and AKT1, and that immunomodulatory biology is a favourable prognostic group before any immunotherapy.

One of the most cited papers Europe PMC returns for Florence Duffaud at Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.

The analysis that put 'left-sided, RAS and BRAF wild-type' into every guideline as the anti-EGFR population, and made an anatomical fact into a treatment-selection biomarker.

The document behind the MRI-first rectal cancer pathway used across Europe and the UK; the total neoadjuvant therapy trials (RAPIDO, PRODIGE 23, OPRA) that came after it are the main reason an update was needed.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

Surgical resection as the only curative treatment and the sequence of systemic options on the lung neuroendocrine tumour page follow this consensus.

The thymoma and thymic carcinoma pages follow this guideline for who gets surgery, radiotherapy and chemotherapy; its central message is that these rare tumours should be discussed in an expert network.

It is the molecular case for sidedness, made before the trial meta-analyses that turned it into a treatment rule, and it supplies the mechanism: ligand dependence on the left, pathway mutation on the right.

A second publication from the BOLERO-2 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT00433589 with the most citations, so it is the natural first reading for anyone following the MINDACT trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

The 55 percent Ki-67 threshold and the recognition that well-differentiated grade 3 tumours behave differently from carcinomas, now embedded in the WHO classification, came from this analysis.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

Doxorubicin-ifosfamide is the standard first-line chemotherapy for advanced MPNST, and the analysis supports treating it like other high-grade sarcomas while recognising its shorter survival.

The definition used in trials and clinics, and the insistence on systemic therapy first and mastectomy rather than breast conservation, come from this document.

This is the paper Europe PMC returns for registry id NCT04493853 with the most citations, so it is the natural first reading for anyone following the CAPItello-281 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

The latest in a line of negative targeted-therapy trials in triple-negative disease (EGFR, VEGF, iniparib, now AKT): a modest delay in progression that did not translate into survival, in the same year that an antibody-drug conjugate did. It is why the roadmap treats pathway-targeted small molecules as the road not taken.

This is the paper Europe PMC returns for registry id NCT03742102 with the most citations, so it is the natural first reading for anyone following the BEGONIA trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

The first-line overall survival result that made an antibody-drug conjugate the standard for PD-L1-negative or immunotherapy-ineligible metastatic triple-negative disease, and the reason the sequencing question (which TROP2 drug first, what after it) is now urgent.

A second publication from the KEYNOTE-671 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

One of the most cited trial reports Europe PMC returns for Trastuzumab deruxtecan in HR-positive / HER2-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.

A second publication from the monarchE trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

A second publication from the trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.